

CYIOS Corporation

258 SouthMilitary Trail
Deerfield Beach, FL 33442

617-504-3635

www.cyioscorporation.com
info@choicewellnessbrands.com

Quarterly Report

For the period ending March 31, 2025 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

280,363,756 as of 03/31/2025 (Current Reporting Period Date or More Recent Date)

280,363,756 as of 12/31/2024 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: ☐ No: ☒

⁴ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

CYIOS Corp.
Formerly=China Printing, Inc. until 11-05
Formerly=WorldTeg Group International, Inc. until 4-05
Formerly=A1 Internet.com, Inc. until 12-01
Formerly=Halo Holdings of Nevada, Inc. until 5-99

Current State and Date of Incorporation or Registration: Nevada, 10/13/1997
Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:
N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:
None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:
On August 2024, the company acquired 100% of the controlling interest in Noir Medical Supplies, LLC, a medical supply wholesaler.

Address of the issuer's principal executive office:

258 South Military Trail Deerfield
Beach, FL 33442

Address of the issuer's principal place of business:
☒ Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Equiniti (formerly Corporate Stock Transfer)
Phone: 651-306-4341
Email: valeen.nowicki@equiniti.com
Address: 1110 Centre Point Curve Suite 101 Mendota Heights, MN. 55120

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>CYIO</u>	
Exact title and class of securities outstanding:	<u>Common Stock</u>	
CUSIP:	<u>23128N108</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>285,000,000</u>	as of date: <u>03/31/2025</u>
Total shares outstanding:	<u>280,363,756</u>	as of date: <u>03/31/2025</u>
Total number of shareholders of record:	<u>144</u>	as of date: <u>03/31/2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of securities outstanding:	<u>Preferred Series A</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>10,000,000</u>	as of date: <u>03/31/2025</u>
Total shares outstanding:	<u>0</u>	as of date: <u>03/31/2025</u>
Total number of shareholders of record:	<u>0</u>	as of date: <u>03/31/2025</u>
Exact title and class of securities outstanding:	<u>Preferred Series B</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>10,000</u>	as of date: <u>03/31/2025</u>
Total shares outstanding:	<u>10,000</u>	as of date: <u>03/31/2025</u>
Total number of shareholders of record:	<u>1</u>	as of date: <u>03/31/2025</u>
Exact title and class of securities outstanding:	<u>Preferred Series C</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>15,000</u>	as of date: <u>03/31/2025</u>
Total shares outstanding:	<u>15,000</u>	as of date: <u>03/31/2025</u>
Total number of shareholders of record:	<u>1</u>	as of date: <u>03/31/2025</u>

Exact title and class of securities outstanding:	<u>Preferred Series D</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>40,000</u>	as of date: <u>03/31/2025</u>
Total shares outstanding:	<u>34,850</u>	as of date: <u>03/31/2025</u>
Total number of shareholders of record:	<u>3</u>	as of date: <u>03/31/2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

There are no defined dividend or preemption rights associated with the common equity. Each share of common stock is entitled to one vote on all shareholder matters.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series A preferred stock. The Series A preferred stock carries a voting right of 20 votes per share and each share is convertible to 20 shares of common stock. There are no dividend, liquidation rights, redemption or sinking fund provisions.

Series B preferred stock. Each holder of outstanding shares of Series B Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock equal to 0.1% of the total number of shares of Common Stock outstanding on the record date for such vote. There are no conversion, dividend, or liquidation rights, redemption or sinking fund provisions.

Series C preferred stock. Each share of Series C Preferred Stock is convertible into a number of common shares equal to .001% of the number of common shares issued and outstanding on the date of conversion. There are no dividend, voting or liquidation rights, redemption or sinking fund provisions.

Series D preferred stock. Each share of Series D Preferred Stock is convertible into a number of common shares equal to .001% of the number of common shares issued and outstanding on the date of conversion. There are no dividend, voting or liquidation rights, redemption or sinking fund provisions.

3. Describe any other material rights of common or preferred stockholders.

NA

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

NA

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/2022</u> Common: 154,731,965 Preferred: 55,250			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
3/23/2023	New	2,104,335	Common	\$0.0225/ share	No	Marko Radisic	Helio Acquisition	Restricted	4(a)(1)
3/23/2023	New	15,832	Common	\$0.0225/ share	No	Stephen Finmore	Helio Acquisition	Restricted	4(a)(1)
3/23/2023	New	18,938	Common	\$0.0225/ share	No	Aki Kotzamichalis	Helio Acquisition	Restricted	4(a)(1)
3/23/2023	New	37,875	Common	\$0.0225/ share	No	Brooker Spanos	Helio Acquisition	Restricted	4(a)(1)
3/23/2023	New	56,813	Common	\$0.0225/ share	No	Tamil Rogeon	Helio Acquisition	Restricted	4(a)(1)
3/23/2023	New	73,932	Common	\$0.0225/ share	No	Vismai Schonfelder	Helio Acquisition	Restricted	4(a)(1)
3/23/2023	New	75,750	Common	\$0.0225/ share	No	Caroline Ale	Helio Acquisition	Restricted	4(a)(1)

3/23/2023	New	83,325	Common	\$0.0225/ share	No	Jolanta Malgorzata Swiderski	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	105,217	Common	\$0.0225/ share	No	George Szafranski	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	105,217	Common	\$0.0225/ share	No	Jeffrey Mullenger	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	105,596	Common	\$0.0225/ share	No	Joe Stephan White	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	110,292	Common	\$0.0225/ share	No	Liang Kwang Lim	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	170,438	Common	\$0.0225/ share	No	Peter James Maddocks	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	199,905	Common	\$0.0225/ share	No	Thomas Strang	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	242,931	Common	\$0.0225/ share	No	Maximiliano Geraldes	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	6,164,502	Common	\$0.0225/ share	No	Finn O'shea	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	1,893,750	Common	\$0.0225/ share	No	Paul Simon Tamas	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	6,921,985	Common	\$0.0225/ share	No	Oscar Leslie O'shea	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	105,634	Common	\$0.0225/ share	No	Jonathon Klingender	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	106,050	Common	\$0.0225/ share	No	Brian Leslie Borrell	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	108,209	Common	\$0.0225/ share	No	Mark Cashmore	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	113,625	Common	\$0.0225/ share	No	Veerabhadra Patil	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	132,033	Common	\$0.0225/ share	No	Robert Ian Jarred	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>

3/23/2023	New	162,333	Common	\$0.0225/ share	No	Dimity Slater	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	284,480	Common	\$0.0225/ share	No	Leigh Smith	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	316,863	Common	\$0.0225/ share	No	Mxg Investments Pty Ltd Max Geraldles	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	396,097	Common	\$0.0225/ share	No	David Greene	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	422,496	Common	\$0.0225/ share	No	Samuel David Westaway	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	858,210	Common	\$0.0225/ share	No	Ian McClure Wightwick	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	132,033	Common	\$0.0225/ share	No	Sleeper Service Pty Ltd Rob Morris	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	110,292	Common	\$0.0225/ share	No	On-Market Bookbuilds Pty Ltd Tim Eisenhaer	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	31,626	Common	\$0.0225/ share	No	The Kop Pty Ltd Servin Davadra	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	132,033	Common	\$0.0225/ share	No	Canada Holdings Pty Ltd Michael Basina	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	198,049	Common	\$0.0225/ share	No	Deadpool Pty Ltd Chris Watson	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	227,250	Common	\$0.0225/ share	No	Mcfaul Rosenthal Pty Ltd Selwyn Mcfaul	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	2,075,134	Common	\$0.0225/ share	No	Segovia 424 Pty Ltd Don Christie	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	264,065	Common	\$0.0225/ share	No	Ben Quin & Claire Quin	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	422,458	Common	\$0.0225/ share	No	Kym Ortenburg	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	1,778,194	Common	\$0.0225/ share	No	I & L Wightwick Pty Ltd Ian Wightwick	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>

3/23/2023	New	264,065	Common	\$0.0225/ share	No	John Quin & Suellen Quin	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	87,113	Common	\$0.0225/ share	No	Kierford Woods Pty Ltd Trust Aki Kotzamichallis	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	528,129	Common	\$0.0225/ share	No	Beaverbrook Holdings Pty Ltd Trust Michael Basina	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	530,250	Common	\$0.0225/ share	No	Salud Investments Pty Ltd Trust Jabe Brown	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/23/2023	New	1,726,646	Common	\$0.0225/ share	No	Kym Ortenburg	<u>Helio Acquisition</u>	<u>Restricted</u>	<u>4(a)(1)</u>
1/3/2023	New	2,000,000	Common	\$0.0097	No	Ryan Clancey	<u>Services</u>	<u>Restricted</u>	<u>4(a)(1)</u>
1/3/2023	New	3,500,000	Common	\$0.001	Yes	Lance Quartieri	<u>Conversion of debt</u>	<u>Restricted</u>	<u>4(a)(1)</u>
1/3/2023	New	10,000,000	Common	\$0.005	Yes	Lance Quartieri	<u>Conversion of debt</u>	<u>Restricted</u>	<u>4(a)(1)</u>
3/31/2023	Cancellation	(2,368,209)	Common	N/A	N/A	Stan Lee Holdings Chris Belland	<u>Cancellation of contract</u>	<u>N/A</u>	<u>N/A</u>
4/1/23	New	3,500,000	Common	\$0.01	Yes	Lance Quartieri	<u>Conversion of debt</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
5/1/23	New	10,000,000	Common	\$0.0153	Yes	Lance Quartieri	<u>Conversion of debt</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
4/21/23	New	1,000,000	Common	\$0.0165	No	Leigh Smith	<u>Compensation</u>	<u>Restricted</u>	<u>4(a)(1)</u>
12/16/23	New	12,000,000	Common	\$0.001 cost per share	Yes	J-RICKS LLC <u>Sarah Leslie</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
12/27/23	New	16,000,000	Common	\$0.001 cost per share	Yes	J-RICKS LLC <u>Sarah Leslie</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
02/21/24	New	16,000,000	Common	\$0.001 cost per share	Yes	J-RICKS LLC <u>Sarah Leslie</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
7/1/24	New	16,000,000	Common	\$0.001 cost per share	Yes	J-RICKS LLC <u>Sarah Leslie</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>

10/10/24	New	8,000,000	Common	\$0.001 cost per share	Yes	J-RICKS LLC <u>Sarah Leslie</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
01/2/2025	(Cancel and return to Treasury)	(3,500,000)	Common	\$.022	No	David Lewis	=	=	=
01/2/2025	(Cancel and return to Treasury)	(3,500,000)	Common	\$.022	No	John O'Shea	=	=	=
01/02/2025	New	1,250	Series D Preferred	Na	Na	David Lewis	<u>Cancellation of 3.5M common shares</u>	<u>Restricted</u>	<u>4(a)(2)</u>
01/02/2025	New	1,250	Series D Preferred	Na	na	John O'Shea	<u>Cancellation of 3.5M common shares</u>	<u>Restricted</u>	<u>4(a)(2)</u>
01/02/2025	New	1,050	Series D Preferred	Na	Na	David Lewis	<u>Employment Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
01/02/2025	New	1,050	Series D Preferred	Na	Na	John O'Shea	<u>Employment Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
01/25/2025	New	7,000,000	Common	\$.0003	Yes	J-RICKS LLC <u>Sarah Leslie</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
Shares Outstanding on Date of This Report:									
<u>Ending Balance</u>									
<u>Ending Balance:</u>									
Date <u>3/31/2025</u> Common: <u>280,363,756</u> Preferred: 59,850									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

☐ Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁵	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
<u>01/10/2016</u>	<u>225,000</u>	<u>70,562</u>	<u>01/17/17</u>	<u>\$.001 per share</u>	167,250,000	70,562,000	<u>J-Ricks LLC</u> <u>Christopher Balmford</u>	<u>Loan</u>
<u>1/2/2020</u>	<u>71,839</u>	<u>94,380</u>	<u>Demand</u>	<u>25% discount to market price at time of conversion</u>	0	15,535,802	<u>OFBP</u> <u>Proprietary Limited</u> <u>John O'Shea</u>	<u>Loan</u>
<u>1/2/2020</u>	<u>6,264</u>	<u>8,948</u>	<u>Demand</u>	<u>N/A</u>	0	N/A	<u>OFBP</u> <u>Proprietary Limited</u> <u>John O'Shea</u>	<u>Loan</u>
<u>6/15/20</u>	<u>20,000</u>	<u>26,059</u>	<u>6/15/21</u>	<u>Fifty Percent (50%) of the lowest Trading Price (defined below) during the twenty (20) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date.</u>	0	7,139,452	<u>GPL Ventures LLC</u> <u>Alex Dillion</u>	<u>Loan</u>
<u>10/14/20</u>	<u>\$20,000</u>	<u>27,346</u>	<u>10/14/21</u>	<u>80% of the average of the three lowest intraday trading prices during the ten (10) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date.</u>	0	4,410,645	<u>GPL Ventures LLC</u> <u>Alex Dillion</u>	<u>Loan</u>
<u>12/7/20</u> <u>1/14/21</u> <u>4/6/21</u> <u>6/10/21</u> <u>12/16/21</u>	<u>\$60,000</u> <u>\$100,000</u> <u>\$100,000</u> <u>\$100,000</u> <u>\$46,666</u>	<u>\$808,153</u>	<u>12/7/21</u> <u>1/14/22</u> <u>4/6/22</u> <u>6/10/22</u> <u>12/16/22</u>	<u>Convertible at \$.012 per share</u>	0	45,262,750	<u>BB Winks LLC</u> <u>Craig Fischer</u>	<u>Loan</u>

⁵ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

<u>12/22/21</u> <u>12/24/21</u>	<u>\$46,666</u> <u>\$46,666</u>		<u>12/22/22</u> <u>12/24/22</u>					
<u>3/20/22</u> <u>5/3/22</u>	<u>\$250,000</u> <u>\$15,002</u>		<u>3/20/22</u> <u>5/3/22</u>	Convertible at \$.025 per share				
<u>2/10/21</u> _____	<u>255,000</u>	<u>\$280,628</u>	<u>02/10/22</u>	Convertible at \$.25 per share	0	1,122,512	<u>EAGLE</u> <u>EQUITIES, LLC</u> <u>Yakov Borenstein</u>	<u>Loan</u>
<u>6/1/21</u>	<u>240,000</u>	<u>\$288,677</u>	<u>6/1/22</u>	Convertible at 12.5 cents per share	0	2,309,416	<u>Adar Bays, LLC.</u> <u>Aryeh Goldstein</u>	<u>Loan</u>
<u>5/4/21</u>	<u>130,000</u>	<u>\$184,935</u>	<u>5/4/22</u>	Convertible at 12.5 cents per share	0	1,479,480	<u>EAGLE</u> <u>EQUITIES, LLC</u> <u>Yakov Borenstein</u>	<u>Loan</u>
<u>12/20/21</u>	<u>\$175,000</u>	<u>\$57,883</u>	<u>12/20/22</u>	Convertible at \$0.005 per share	0	11,576,600	<u>Lance Quartieri</u>	<u>Loan</u>
<u>4/18/22</u>	<u>\$50,000</u>	<u>\$55,400</u>	<u>4/18/23</u>	N/A	0	N/A	<u>J-Ricks LLC</u> <u>Christopher</u> <u>Balmford</u>	<u>Loan</u>
<u>6/15/22</u>	<u>\$30,000</u>	<u>\$5,000</u>	<u>On</u> <u>Demand</u>	N/A	0	N/A	<u>DBL Group</u> <u>Bruce Lewis</u>	<u>Loan</u>
<u>7/13/22</u>	<u>\$9,800</u>	<u>\$11,000</u>	<u>On</u> <u>Demand</u>	N/A	0	N/A	<u>DBL Group</u> <u>Bruce Lewis</u>	<u>Loan</u>
<u>7/11/22</u>	<u>\$87,000</u>	<u>\$87,000</u>	<u>9/15/22</u>	N/A	0	N/A	<u>Lance Quartieri</u>	<u>Loan</u>
<u>6/30/24</u>	<u>\$230,997</u>	<u>\$230,997</u>	<u>6/30/2025</u>	85% of any future public offering share price	0	33,970,147	<u>J-Ricks LLC</u> <u>Sarah Leslie</u>	<u>Loan</u>
<u>7/29/24</u>	<u>\$25,000</u>	<u>\$25,000</u>	<u>7/28/2025</u>	85% of any future public offering share price	0	3,086,419	<u>Ralph Amato</u>	<u>Loan</u>
<u>12/31/24</u>	<u>\$125,103</u>	<u>\$125,103</u>	<u>12/31/25</u>	85% of any future public offering share price	0	18,397,500	<u>J-Ricks LLC</u> <u>Sarah Leslie</u>	<u>Loan</u>

Total Outstanding Balance: \$2,387,071

Total Shares: 167,250,000 215,852,723

Any additional material details, including footnotes to the table are below:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.

Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

CYIOS Corporation (the Company) is incorporated in the State of Nevada. The Company focuses on innovative tech, blockchain, Web3/NFT and carbon offsets with several subsidiary businesses including Helio Lending, Randombly, Immortals Group, CarbonCred.io platform, and Noir Medical Supplies, LLC. In May 2021, the Company acquired Helio Lending. Helio is a CeFi (Centralized Finance) aggregator providing customers with a wide array of loan structures available to cryptocurrency owners with competitive rates on a global basis from a variety of loan vendors. Helio does not hold crypto nor provide direct lending from our own account. However, Helio strictly acts as a referral partner to our lending panel and receives a fee for referring parties to direct lenders. In 2023 the company launched Carboncred.io, an innovative carbon offsetting platform that empowers businesses, families, and consumers to reduce their carbon footprint quickly and easily by purchasing carbon offsets that support a variety of verified carbon offsetting projects via monthly subscription plans. In August 2024, the company acquired 100% of the controlling interest in Noir Medical Supplies, LLC, a medical supply wholesaler.

B. List any subsidiaries, parent company, or affiliated companies.

- Choice Wellness Inc., a Wyoming corporation, wholly owned subsidiary (as of May 7, 2020)
- Helio Lending, PTY., an Australian corporation, wholly owned subsidiary (as of May 2021)
- Immortals Group, PTY, an Australian corporation wholly owned subsidiary (as of April 1st 2022)
- Ranbomby LLC, a Florida corporation, wholly owned subsidiary (as of January 5th, 2022)
- Noir Medical Supplies, LLC, a Florida company, wholly owned subsidiary (as of August 10, 2024)

C. Describe the issuers' principal products or services.

Helio Lending PTY, is a CeFi aggregator providing customers access to a panel of affiliate lenders to choose from with a wide array of loan structures available to cryptocurrency owners with competitive rates. The Company does not provide direct lending of its own capital to customers nor does the Company hold crypto of its own or for customers. Carboncred.io is an innovative carbon offsetting platform that empowers businesses, families, and consumers to reduce their carbon footprint quickly and easily by purchasing carbon offsets that support a variety of verified carbon offsetting projects via monthly subscription plans. Noir Medical Supply is a wholesaler of medical supplies.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company leases space for \$500 per month on a month-to-month basis.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer’s securities.
If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
David Lewis	CEO/Director	Boca Raton, FL	16,560	Series D Preferred	41.4%
John O'Shea	Director/Chairman of the Board	Melbourne, Australia	10,000	Series B Preferred	100%
			15,000	Series C Preferred	100%
			4,800	Series D Preferred	12%

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person’s involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a “yes” answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person’s involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

In the Matter of Traci J. Anderson, CPA, Timothy W. Carnahan, and CYIOS Corporation (File No. 3-16386). On February 3, 2020 the Company filed its Petition for Review of the Initial Decision in this matter. The Petition is pending, and the Company intends to vigorously pursue the Petition and any additional appeals, if necessary

On February 13, 2015, the Securities and Exchange Commission entered an “Order Instituting Administrative And Cease- And-Desist Proceedings” The SEC alleged that the Company, its then CEO Timothy Carnahan and its accountant Traci J. Anderson violated certain provisions of the Sarbanes-Oxley Act of 2002, the Securities Exchange Act of 1934 and certain rules promulgated thereunder including the failure to properly assess the Company’s internal controls. Ms. Anderson was dismissed from the action on December 21, 2015. On June 21, 2018, “[i]n light of the Supreme Court’s decision in Lucia v. SEC,” 138 S. Ct. 2044 (2018), the Commission stayed all pending administrative proceedings, including this one; the stay was operative through August 22, 2018. On August 22, 2018, the Commission ended the stay and ordered a new hearing in each affected proceeding before an administrative law judge who had not previously participated in the proceeding. On January 10, 2020, the Administrative Law Judge entered an initial decision seeking a cease and desist against the Company and Carnahan and seeking to impose monetary penalties against the Company in excess of \$500,000. On February 3, 2020, the Company filed its Petition for Review of the Initial Decision. On January 25, 2021 the Administrative Law Judge granted the Company’s Petition for Review and set a briefing schedule. The Company has filed its initial and reply briefs in the matter. Former CEO Carnahan has filed a separate brief on his own behalf. **On June 2, 2023, the SEC issued an Order dismissing the proceeding. In doing so, the SEC vacated the cease and desist sanction, as well as the disgorgement and civil penalty.**

CYIOS Corp. v Carnahan, CASE NO. CACE-21-007984, Circuit Court of the 17th Judicial District in and For Broward County, Florida. On April 20, 2021 the Company filed a lawsuit against Timothy W. Carnahan, the former CEO of the Company. The Complaint contains six causes of action including breach of fiduciary duty, Gross Negligence, Unjust

enrichment, Disgorgement pursuant to Section 304 of the Sarbanes Oxley Act of 2002, Declaratory Relief, and a Temporary Restraining Order. The Company alleges that Mr. Carnahan acted outside the scope of his authority in issuing to himself 5,000,000 shares of common stock as a performance bonus. The Company believes that the shares should be returned to the Company and canceled.

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Jonathan Leinwand, Esq.
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18305 Biscayne Blvd., Suite 200
Address 2: Aventura, FL 33160
Phone: 954-903-7856
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: J.D. Patterson
Firm: Patterson CPAs, LLC
Address 1: 722 West Shepard Lane, Suite 101
Address 2: Farmington, UT 84025
Phone: 801-451-8886
Email: john@gapcpas.com

Investor Relations

Name: N/A
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

Twitter: @cyioscorp
Discord: N/A
LinkedIn: n/a
Facebook: N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: N/A

Firm: N/A
Address 1: N/A
Address 2: N/A
Phone: N/A
Email: N/A

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: David Lewis
Title: CEO
Relationship to Issuer: CEO

B. The following financial statements were prepared in accordance with:

- ☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: John Patterson
Title: Accountant
Relationship to Issuer: Service Provider

Describe the qualifications of the person or persons who prepared the financial statements:⁶ Mr. Paterson is a licensed certified public accountant in good standing with extensive experience in preparing, reviewing and auditing public company financial statements in accordance with US GAAP.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

⁶ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, David Lewis certify that:

- 1. I have reviewed this Disclosure Statement for CYIOS Corporation;
- 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
- 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

5/20/2025 [Date]

/S/ David Lewis [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, John O'Shea certify that:

- 1. I have reviewed this Disclosure Statement for CYIOS Corporation;
- 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
- 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/20/2025 [Date]

/S/ John O'Shea [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

CYIOS Corporation

**Consolidated Financial Statements
Unaudited**

**For the Quarter Ended
March 31, 2025**

CONTENTS

	Page
CONSOLIDATED BALANCE SHEET	3
CONSOLIDATED STATEMENTS OF NET INCOME (LOSS).....	4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY	5
CONSOLIDATED STATEMENTS OF CASH FLOWS.....	6
NOTES TO FINANCIAL STATEMENTS	7

CYIOS CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)

	As of March 31, 2025	As of December 31, 2024
ASSETS		
Cash	\$ 6,687	\$ 29,191
Accounts Receivable	521,755	252,600
Inventory	108,935	85,703
Related Party Receivable	-	180,000
Prepaid and Other Current Assets	33,529	65,505
Total Current Assets	<u>670,906</u>	<u>612,999</u>
Investments	75,000	96,233
Goodwill	250,000	250,000
TOTAL ASSETS	<u><u>995,906</u></u>	<u><u>959,232</u></u>
LIABILITIES AND SHAREHOLDERS' DEFICIT		
Accounts Payable and Accrued Expenses	\$ 850,103	\$ 623,819
Current Portion of Convertible Notes	1,741,539	1,701,555
Promissory Notes	313,452	545,499
Related Party Convertible Note	96,821	95,600
Related Party Payable	19,082	18,878
Total Current Liabilities	<u>3,020,997</u>	<u>2,985,351</u>
SHAREHOLDERS' DEFICIT		
Common Stock, \$.001 par value, 285,000,000 shares authorized, 280,363,756, and 280,363,756 shares issued and outstanding, respectively	280,364	280,364
Preferred Stock	61	56
Additional Paid-in Capital	29,975,959	29,909,764
Common Stock Issuable	237,942	226,142
Retained Deficit	(32,669,415)	(32,442,445)
Total Shareholder's Deficit	<u>(2,175,090)</u>	<u>(2,026,119)</u>
LIABILITIES AND SHAREHOLDERS' EQUITY	<u><u>\$ 845,907</u></u>	<u><u>\$ 959,232</u></u>

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

CYIOS CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

	For the Three Months Ended March 31,	
	2025	2024
INCOME		
Revenues	\$ 2,522,901	\$ -
Less:		
Cost of Revenues	<u>2,234,475</u>	<u>-</u>
Gross Profit	288,426	-
EXPENSES		
Advertising and Promotion	36,926	2,165
Consulting	-	10,250
Legal and Professional Fees	22,645	1,180
Salaries & Wages	114,932	-
Commissions	201,054	-
General and Administrative	<u>57,197</u>	<u>97,755</u>
Total Expenses	432,754	111,350
Income (Loss) from Operations	(144,328)	(111,350)
Other Income and Expense		
Interest Expense	(82,643)	(158,810)
Impairment of Assets	-	-
Other Income (Expense)	<u>-</u>	<u>(1,875)</u>
Total Other Income and Expense	(82,643)	(160,685)
NET LOSS	<u>\$ (226,970)</u>	<u>\$ (272,035)</u>

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

CYIOS CORPORATION
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(Unaudited)

	Common Stock		Preferred Stock		Additional	Common Stock	Retained	
	Shares	Amount	Shares	Amount	Paid-In Capital	Issuable	Deficit	Total
Balance as of December 31, 2022	154,731,956	\$ 154,732	55,250	\$ 56	\$ 28,561,996	\$ 680,142	\$ (30,860,801)	\$ (1,463,875)
Issuance of shares owed	30,000,000	30,000	-	-	645,000	\$ (675,000)	-	-
Stock issued for services	3,000,000	3,000	-	-	32,900	-	-	35,900
Stock issued on debt conversion	55,000,000	55,000	-	-	424,000	-	-	479,000
Stock cancelled	(2,368,200)	(2,368)	-	-	(197,732)	-	-	(200,100)
Net loss for the period	-	-	-	-	-	-	\$ (274,167)	(274,167)
Balance as of December 31, 2023	240,363,756	\$ 240,364	55,250	\$ 56	\$ 29,466,164	\$ 5,142	\$ (31,134,968)	\$ (1,423,242)
Conversion of accrued salary to stock	-	-	-	-	114,000	6,000	-	120,000
Stock issuable for services contract	-	-	-	-	-	140,000	-	140,000
Stock issued on debt conversion	40,000,000	40,000	-	-	329,600	-	-	369,600
Acquisition of Noir	-	-	-	-	-	75,000	-	-
Net loss for the period	-	-	-	-	-	-	(1,307,477)	(1,307,477)
Balance as of December 31, 2024	280,363,756	\$ 280,364	55,250	\$ 56	\$ 29,909,764	\$ 226,142	\$ (32,442,445)	\$ (2,101,119)
Common stock issuable for interest	-	-	-	-	-	17,800	-	17,800
Common stock converted to preferred	(7,000,000)	(7,000)	4,600	5	12,995	(6,000)	-	-
Stock issued on debt conversion	7,000,000	7,000	-	-	53,200	-	-	60,200
Net loss for the period	-	-	-	-	-	-	(226,970)	(226,970)
Balance as of March 31, 2025	280,363,756	\$ 280,364	59,850	\$ 61	\$ 29,975,959	\$ 237,942	\$ (32,669,415)	\$ (2,250,089)

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

CYIOS CORPORATION
CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited)

	For the Three Months Ended March 31,	
	2025	2024
CASH FROM OPERATING ACTIVITIES		
Net Loss	\$ (226,970)	\$ (272,035)
Adjustments to reconciled net loss to net cash flow from operating activities:		
Depreciation and Amortization	-	1,875
Loss (gain) on disposition of assets	21,233	-
Stock issued for interest expense	71,000	158,400
Change in operating accounts:		
Decrease in accounts receivable	(269,155)	-
Increase in inventory	(23,232)	-
(Increase) decrease in prepaid expenses	31,976	8,750
Increase in accounts payable and accrued expenses	226,284	28,107
Net Cash Used in Operating Activities	(168,865)	(74,903)
CASH FROM INVESTING ACTIVITIES	-	-
CASH FROM FINANCING ACTIVITIES		
Net proceeds from issuance of convertible notes	40,000	-
Proceeds from issuance of promissory notes	106,361	72,112
Net proceeds from related party borrowing	-	-
Net Cash Used in Financing Activities	146,361	72,112
Net change in cash and cash equivalents	(22,504)	(2,790)
Cash at beginning of period	29,191	6,657
Cash at the end of period	\$ 6,687	\$ 3,867
SUPPLEMENTAL CASH FLOW INFORMATION		
Cash Paid During the Period for:		
Taxes	\$ -	\$ -
Interest	\$ -	\$ -
Non-Cash Activities		
Stock issued to retire debt and interest	\$ 78,000	\$ 174,400
Common stock issuable under services contract	\$ (6,000)	\$ 140,000
Common stock issued on conversion of accrued salary	\$ -	\$ 120,000

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

CYIOS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Quarter Ended March 31, 2025

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

The Company's accounting policies conform to U.S. Generally Accepted Accounting Principles (USGAAP). The following policies are considered to be significant:

Business Organization

CYIOS Corporation (the Company) is incorporated in the State of Nevada. The Company was reorganized to engage in the business of developing and marketing specialty branded products in the Health and Wellness markets. The Company is currently headquartered in Florida. At this time, the Company is revenue producing and is selling products under its own private label and other branded products in the Health and Wellness market segment. On May 7, 2020, the Company acquired Choice Wellness Inc. In May, 2021, the Company acquired the assets of Helio Lending for a total of 15,000,000 shares of common stock and a commitment to issue an additional 15,000,000 common stock pending the realization of achieving certain revenue targets. The Company recorded a stock payable for \$675,000 to reflect this obligation which has been offset to Goodwill as the assets are intangible in nature. During the year ended December 31, 2023, the Company issued 30,000,000 shares of restricted common stock in stock to satisfy this obligation. During the year ended December 31, 2024, the Company determined that it was no longer feasible to continue the operations of Helio Lending and closed the associated operations thereof. As a result, the Company recorded a loss on disposition of assets of \$675,000 related to the recorded Goodwill. On August 10, 2024, the Company acquired 100% of the issued and outstanding ownership of Noir Medical Supply, LLC, a Florida company engaged in providing medical supplies, in exchange for six million (6,000,000) shares of CYIOS common stock.

The Company activities are subject to significant risks and uncertainties, including failing to secure the necessary funding to operationalize it plans.

Revenue Recognition / Source of Funding

The provisions of the FASB's ASC Topic 606, Revenue from Contracts with Customers, have been analyzed. It has been concluded that no changes are necessary to conform with the new standard. The program service fees are recognized at a point in time when service is provided, technical ownership, risks, and rewards are transferred. Funds received in advance of providing the services are recorded as deferred income until the services are provided. Contributions are recognized when pledged and recorded as net assets without donor restrictions or net assets with donor restrictions, depending on the existence and/or nature of any donor-imposed restrictions. Gifts of cash and other assets are reported with donor restricted support if they are received with donor stipulations that limit the use of the donated assets. When a restriction expires, that is, when a stipulated time restriction ends or a purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. The company only bills customers once services or goods are provided and income is considered earned. The Company does not engage in progress billing.

Principles of Consolidation

The consolidated financial statements include the Company's wholly owned subsidiaries, Choice Wellness, Inc., Randombly, LLC, Helio Lending, and Noir Medical Supply, LLC. All significant intercompany transactions are eliminated. There was no income or expense recorded between the companies during the year ended December 31, 2024. For Noir Medical Supply, only the results of operations from the date of acquisition (August 10, 2024) through period end date have been consolidated. The difference between the value of the shares issued to acquire Noir (\$75,000), and the net assets acquired (\$400,809), were recorded as a gain in Other Income as of the acquisition date.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with USGAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the reporting period. In these financial statements, assets, liabilities, and earnings involve reliance on management's estimates. Actual results could differ from those estimates.

NOTE 2 - CONVERTIBLE NOTES PAYABLE

During January of 2016, the Company entered into a \$225,000 Convertible Loan Agreement with Azure Associates in exchange for non-assessable shares of the Company's Common Stock based upon a conversion price of \$.0003 per share with interest accruing at 0%. To comply with US GAAP, Company has applied an interest rate of 2.65% based upon the long-term federal funds rate when the convertible bond was issued. As of August 31, 2019, the Company agreed to restructure the convertible debt from a conversion price of \$.0003 per share to \$.001 per share. During the year ended December 31, 2021, the Company converted \$39,106, including interest. During the nine months ended September 30, 2022, the Company converted an additional \$10,000 of principle for 6,500,000 shares of common stock. During the quarter ended March 31, 2023, an additional \$3,500 was converted into 3,500,000 shares of common stock. During the quarter ended December 31, 2023, the Company issued 28,000,000 shares on the conversion of \$28,000 in principal, leaving a balance due as of December 31, 2023 is \$110,562. During the three months ended March 31, 2024, the Company issued an additional 16,000,000 shares of restricted common stock on the conversion of \$16,000 in note principal. 16,000,000 shares were issued on the conversion of \$16,000 in accrued interest on July 1, 2024 and 8,000,000 shares were issued on the conversion of \$8,000 in principle on October 10, 2024. During the quarter ended March 31, 2025, an additional 7,000,000 shares were issued on the conversion of \$7,000 in principle, leaving a balance owed of \$63,562 as of March 31, 2025.

During the year ended December 31, 2021, the Company issued a \$255,000 a 6% per annum redeemable note. The note is due on February 10, 2022 and is convertible into common stock at a fixed price of .25 cents per share. As of March 31, 2025, the balance due was \$255,000.

During the year ended December 31, 2021, the Company issued a \$240,000 6% per annum convertible bond. The note is convertible into common stock at a fixed price of 12.5 cent per share. As of December 31, 2024, the balance due on the note was \$240,000. In May 2024, the Company was notified that the lender, Adar Bay, had been sanctioned by the Securities and Exchange Commission and that, as a result, all convertible features of this debt had been cancelled. As there were no derivative features associated with this loan, there is no impact of this change on the financial statements of the Company

During the year ended December 31, 2021, the Company issue a \$130,000 6% annum convertible bond due on May 4, 2022. The note is convertible into common stock at a fixed price of 12.5 cents per share. As of March 31, 2025, the balance due on the note was \$130,000.

During the year ended December 31, 2020, the Company entered into agreement with BB Winks LLC for a convertible grid promissory note for up to \$500,000. The initial terms required \$60,000 in initial funding prior to December 31, 2020. The note accrues interest annually at 8% per annum and any loans provided require payment within one year in cash or for common stock with a fixed price of \$.012 per share. At no time will the Company issue common shares that would result in the lender owning more that 9.99% of the common stock outstanding at the time of conversion. A total of \$500,000 has been drawn down against this note as of December 31, 2022. A second convertible grid promissory note for up to \$500,000 was entered into in during the year ended December 31, 2022 under same terms but with a fixed conversion price of .025 per share. As of March 31, 2023, a total of \$245,000 had been drawn down under this note. The total balance owed to BB Winks under both notes as of March 31, 2025 was \$745,000.

On December 20, 2021, the Company issued a convertible note payable to Lance Quartieri in the amount of \$175,000

which is due 12 months from the date of issuance. The note is convertible into common shares of the Company stock at \$0.005 per share. In the quarter ended March 31, 2023, \$50,000 of this note was converted into 10,000,000 shares of common stock. In the quarter ending June 30, 2023, an additional \$67,500 was converted into 13,500,000 shares of common stock. As of March 31, 2025, the remaining principal balance due is \$57,500.

On June 30, 2024, the Company executed an 8% interest, 12-month convertible note payable with J-Ricks, LLC in the amount of \$200,000. The total advanced was later increased and \$368,509 had been paid to the Company as of March 31, 2025. Under the terms of the note, the payee has the option to convert the balance of any outstanding principal and interest into common stock of the Company at 85% of the sales price of any future public offering of the Company's common stock. The payee is aware that the Company is not presently contemplating any public stock offerings.

In February 2025, the Company executed three convertible notes of \$25,000 each, totaling \$75,000, to three unrelated individuals. As of March 31, 2025, \$25,000 had been received from one individual and \$15,000 from another. Subsequent to March 31, 2025, \$25,000 was received from the third individual and the remaining \$10,000 from the second. The notes are due February 9, 2026, earn interest at the rate of 10% per annum and are convertible into common stock at a share price equal to 65% of the average of the three lowest End of Day VWAP for the Common Stock during the 7 trading days preceding the Conversion Date, but in no event less than \$.00025 per share. As consideration for issuing the notes, each of the three lenders will be issued 1,000,000 shares of common stock, of which 2,000,000 shares valued at \$11,600 were recorded as Common Stock Issuable in the accompanying financial statements based on the value of the stock on the date the monies were received.

Combined, the Company has convertible notes outstanding, together with accrued interest, of \$1,741,539 as of March 31, 2025.

NOTE 3 - RELATED PARTY PAYABLE

The Company entered into a loan agreement with OFBP Proprietary Limited (OFBP Pty Ltd) in the fourth quarter of 2018, for up to \$250,000 to pay for operational expenses. As of December 31, 2020, the balance under this loan was \$71,839. Interest accrued at 15% per annum on the outstanding balance. On January 2nd 2020, in exchange of this loan, the Company issued a one-year Convertible Promissory Note to OFBP Pty, Ltd in the amount of \$71,839 for payments made by the investor on behalf of the Company to various third-party vendors, at the direction of the Company, during 2019. General terms of the Note are 6% annual interest and conversion terms of 25% discount into common shares. As of March 31, 2025, the balance of the Convertible Note Payable was \$96,820 including interest.

Beginning January 2, 2020, any new funds provided by OFBP will be a loan payable at 8% annual interest. During the year ended September 30, 2020, \$7,048 in payments made by the investor on behalf of the Company to various third-party vendors, at the direction of the Company. The Company closed out the agreement with OFBP during the 2nd quarter of 2020. As of March 31, 2025, the balance of the note payable, including interest, was \$13,082.

During the year ended December 31, 2024, the Company borrowed \$30,000 from the CEO of Noir, in the form of note convertible at 85% of the offering price of any future Reg A offering of CYIOS.

NOTE 4 - RELATED PARTY RECEIVABLE

During the year ending December 31, 2024, the Company loaned a total of \$180,000 to the Company's Chief Executive Officer in lieu of compensation. The balance, together with accrued interest at the rate of five percent (5%) is due before the end of 2025.

NOTE 5 - COMMON STOCK ACTIVITY

The Company is authorized to issue 285,000,000 shares of common stock at \$.001 per share, of which 280,363,756 shares were issued and outstanding as of March 31, 2025.

During the three months-ending March 31, 2023, the Company has the following common stock activity:

- 13,500,000 shares were issued on the conversion \$53,500 in convertible notes payable.
- 2,000,000 shares were issued in satisfaction of legal services performed.
- 30,000,000 shares issued to complete acquisition of Helio Lending
- 2,368,209 shares previously issued to acquire a license agreement were returned to the Company and cancelled (see Note 5).

During the three months ending June 30, 2023, the Company had the following common stock activity:

- 13,500,000 shares were issued on the conversion of \$62,500 in convertible notes payable.
- 1,000,000 shares were issued in satisfaction of a consulting agreement. On the date of issuance, the shares had a value of \$16,500.

There was no common stock activity during the three months-ending September 30, 2023.

During the three months-ending December 31, 2023, the Company issued 28,000,000 shares on the conversion of \$28,000 in convertible notes payable that were originally issued to Azure Associates. The company recorded additional interest in the amount of \$138,700 resulting from the difference between the conversion price (\$.001) and the closing bid price on the date of conversion.

During the three months ending March 31, 2024, the Company issued 16,000,000 shares on the conversion of \$16,000 in convertible notes payable that were originally issued to Azure Associates. The company recorded additional interest in the amount of \$158,400 resulting from the difference between the conversion price (\$.001) and the closing bid price on the date of conversion.

There was no common stock activity during the three months ending June 30, 2024.

During the three months ending September 30, 2024, the Company issued 16,000,000 shares of common stock in to J-Ricks on the conversion of \$16,000 in accrued interest related to a convertible note originally issued to Azure Associates in January 2016.

During the three months ending December 31, 2024, the company issued 8,000,000 shares to J-Ricks on the conversion of \$8,000 in convertible note principle.

During the three months ending March 31, 2025, the Company issued 7,000,000 shares to J-Ricks on the conversion of \$7,000 in convertible note principle. On January 2, 2025, the Company cancelled 3,500,000 shares previously issued to each of the Company's directors under their employment agreements in exchange for 2,500 shares of Preferred Stock, Series D.

NOTE 5 - COMMON STOCK ISSUABLE

During 2020, the Company converted 10,000 shares of Preferred Series B into 2,348,103 shares valued at \$35,222. Additionally, the Board of Directors (Board) authorized the issuance of 3,500,000 shares of common stock to the chairman of the board and the chief executive officer for professional services rendered effective October 1, 2020. The closing price per share on that date was \$.02 placing the value for both issuances at \$140,000. Those shares were issued in the 1st Quarter of 2021. Additionally, the Board authorized the issuance of 500,000 shares at the same \$.02 closing price to be issued to a vendor in exchanges for consulting services provided to the Company. In April 2021, the Company acquired the assets of

Helio Lending, which amounted to software and other intangible assets in exchange for the future issuance of 15 million shares of common stock, which were valued at \$675,000 on the date of the agreement. 1,504,000 shares were issued during the three months ending September 30, 2022 related to these obligations. During the three months ending March 31, 2023, the Company issued 30,000,000 shares in satisfaction of the balance of the obligation.

In November 2021, the Company entered into a licensing agreement, pursuant to which the Company was obligated to pay \$100,000 in cash and issue common stock valued at \$200,000 on the date of issuance. Subsequent to December 31, 2021, the Company issued 2,368,209 shares of common stock in satisfaction of this obligation. The value of the shares, \$200,000, was recorded as common stock issuable as of December 31, 2021. These shares were subsequently issued in the three months ending March 31, 2022. Subsequent to December 31, 2022, all shares previously issued under the license agreement were returned and cancelled, with the underlying license agreement being likewise cancelled. As a result of this transaction, the Company reversed the value of the shares issued (\$200,000) and incurred a further decline in value of the asset of \$467,698, which has been recorded in Other Expense as of December 31, 2022. During the three months ending September 30, 2023, the Company received \$400,000 as consideration for the cancellation of the license agreement which was recorded as Other Income in the accompanying financial statements.

During the quarter ending March 31, 2024, the Company's officers each agreed to convert \$60,000 in accrued wages (\$120,000 total) into common stock of the Company at an agreed conversion rate of \$0.02 per share (6,000,000 shared total). These shares had not been issued as of December 31, 2024 and were recorded as Stock Subscription Payable. In March 2025, the Company agreed to issue 2,100 shares of Series D Preferred Stock in lieu of issuing to common shares.

During the quarter ending March 31, 2024, the Company entered into a 12-month consulting contract with Intent Sciences, LLC, pursuant to which the Company is obligated to issue common stock with a value of \$140,000, with an initial payment of 6,000,000 shares. No shares had been issued under the contract as of September 30, 2024, resulting in \$140,000 being recorded as Stock Subscription Payable.

On August 10, 2024, the Company consummated the acquisition of 100% of the controlling interest in Noir Medical Supplies, LLC in exchange for 6,000,000 shares of CYIOS common stock. The value of the stock on the date of acquisition, \$75,000, has been recorded as Stock Payable as of December 30, 2024 pending the physical issuance of the shares.

In February 2025, the Company agreed to issue a total of 3,000,000 shares of common stock as consideration for receiving notes payable totaling \$75,000, of which \$40,000 had been received as of March 31, 2025. The Company also received a \$15,000 working capital loan in February 2025 which was repaid in March 2025. As consideration for this loan, the Company agreed to issue 1,000,000 shares of common stock which had not been issued as of March 31, 2025. Accordingly, the Company recorded the value of 3,000,000 shares as of the date the funds were received (\$17,800) as Common Stock Issuable.

As of March 31, 2025, the Company has common stock issuable of \$237,942

NOTE 6 - PREFERRED STOCK

As of March 31, 2025, the Company has authorized 15,000,000 preferred shares of which 4,940,000 remain undesignated.

Series A

The Company has authorized the issuance of up to 10,000,000 shares of \$.001 par value Series A preferred stock. The preferred stock carries a voting right of 20 votes per share and each share is convertible to 20 shares of common stock. During the year ending December 31, 2021, the Company had previously issued 10,000,000 shares of preferred stock which were returned as part of the settlement with a former CEO.

Series B

As of March 31, 2025, the Company is authorized the issue of up to 10,000 shares of \$.001 par value Series B preferred stock. Each holder of outstanding shares of Series B Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock equal to 0.1% of the total number of shares of Common Stock outstanding on the record date for such vote. In the quarter ending March 31, 2021, the Company had previously issued 10,000 shares of preferred stock to David Green for his service as CEO. Those shares were later converted to 2,348,103 common shares at \$.015 per share. Subsequently, the 10,000 shares of Series B we issued to Mr. John O'Shea at par value for services to the Company.

Series C

As of March 31, 2025, the Company is authorized to issue up to 15,000 shares of \$.001 par value Series C preferred stock. During the year ending December 31, 2020, the Company issued 15,000 shares of Series C to Mr. John O'Shea at par value for services to the Company. Each share of Series C Preferred Stock is convertible into a number of common shares equal to .001% of the number of common shares issued and outstanding on the date of conversion.

Series D

As of March 31, 2025 the Company is authorized to issue of up to 40,000 shares of \$.001 par value Series D preferred stock. As of September 30, 2020, the Company had issued 20,000 shares of preferred stock to acquire Choice Wellness, Inc. Additionally, 2,500 and 10,000 shares of Series D were issued at par value to Mr. John O'Shea and Mr. David Lewis, respectively, for services provided (2,500 to each for services provided to the Board of Directors and the other 7,500 to Mr. Lewis for service as the Chief Executive Officer (CEO). Each share of Series D Preferred Stock is convertible into a number of common shares equal to .001% of the number of common shares issued and outstanding on the date of conversion. During the year ending December 31, 2022, 2,250 shares of Series D stock were converted to 3,183,750 shares of common stock. During the three months ended March 31, 2025, the Company agreed to issue to John O'Shea and David Lewis, directors of the Company, a total of 4,600 shares of Series D in exchange for the cancellation of 7,000,000 shares of common stock and the conversion of 6,000,000 shares of common stock issuable from the prior cancellation of accrued salary.

NOTE 7 - PURCHASE OF SUBSIDIARIES

On August 10, 2024, the Company acquired 100% of the controlling interest in Noir Medical Supplies, LLC in exchange for 6,000,000 shares of CYIOS common stock, which was valued at \$75,000 on the date of closing. Net assets of Noir (assets less liabilities) on August 10, 2024 were \$400,809. The difference between the purchase price and the net asset value, \$325,809, has been recorded as a gain on acquisition during the period ending September 30, 2024. The balance sheets of Noir have been consolidated for all periods presented.

NOTE 8 - SUBSEQUENT EVENTS

Management noted that there have been no material transactions from the period ending March 31, 2025 through the date of this report.